Video

The Impact of PCSK9 Inhibitors on Specialty Pharmacy

Author(s):

Lauren Santye, Assistant Editor

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Related Videos
Image credit: JJAVA | stock.adobe.com
Related Content
Composition with pills of Bayer Aspirin
April 17th 2025

High-Dose Aspirin With IVIG Does Not Meaningfully Reduce Coronary Artery Lesions in Children With Kawasaki Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Gut health -- Image credit: sdecoret | stock.adobe.com
April 16th 2025

Essential Immune Cells in Intestine Cause Gut Inflammation, Allergic Responses to Foods When Absent

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Health care professional hands holding a hepatitis liver -- Image credit: mi_viri | stock.adobe.com
April 15th 2025

Study: Hepatic PTPRD Expression Impaired in Etiologies of Chronic Liver Disease Associated With Metabolic Disease

Gillian McGovern, Associate Editor
Pharmacist in specialty pharmacy preparing oral oncolytics -- Image credit: Monet | stock.adobe.com
April 15th 2025

Outcomes of Pharmacist-Driven Clinical Interventions in a Medically Integrated Oncology Specialty Pharmacy Practice

Natalie Kaufman, PharmD Nicole Bentivegna, PharmD, BCOP Roger Orr, PharmD, BCOP